Royalty Pharma

Historical price data

Founded in 1996, Royalty Pharma pioneered the royalty pharma asset class by providing non-dilutive capital to pharmaceutical innovators. The company has deployed over $19 billion to acquire royalty interests in leading medicines across multiple therapeutic areas. As a publicly-traded company on NASDAQ, Royalty Pharma generates revenue from royalty payments on successful drugs while helping fund the next generation of medical breakthroughs.

Royalty acquisition and portfolio management platform that provides capital to biopharmaceutical innovators in exchange for royalty interests in their products.

Total raised: $2.2B

Royalty Pharma competes with other specialty pharma royalty companies, investment funds, and traditional funding sources. The company differentiates itself through scale, expertise, established relationships, and ability to provide significant capital commitments to support innovation.